Últimas noticias sobre Eli Lilly (NYSE:LLY) Bolsa

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

US CHINA FLAG Photo by asiandelight on Shutterstock

Government

News

Tech

Media

AAPL

NVDA

Michael Kratsios toma las riendas de la inteligencia artificial en EE. UU. con un plan estratégico para contener a China.

Michael Kratsios lidera estrategia de IA en EE. UU. para frenar el avance de China

Movers_Stocks

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADPT

CXAI

ENTO

HRTG

IIIN

LION

LSAK

MLNK

MULN

OLMA

RNAC

SGMO

SHCO

SLSR

Sangamo Therapeutics se dispara tras anunciar un acuerdo exclusivo con Eli Lilly sobre tecnología genética patentada. ¿Qué implica esto?

Acciones de Sangamo Therapeutics (SGMO) se disparan un 40%; Aquí están 20 acciones que se mueven en premercado

AMGN

Amgen lanza ensayos de fase 3 para MariTide, su inyección contra la obesidad. ¿Podrá competir con Ozempic y Wegovy? Descubre su potencial.

Amgen (AMGN) desafía a Novo Nordisk y Eli Lilly con MariTide: ¿Una nueva era para la obesidad?

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

U.S. stock futures declined on Friday after a bloodbath on Thursday following the introduction of President Donald Trump&#8216;s tariffs. Futures of major benchmark indices were lower in premarket trading.
Fueled by a broad market downturn, the Dow Jones plummeted by a staggering 1,679 points, its fifth-largest drop ever, while the S&amp;P 500 and Nasdaq suffered their biggest single-day losses since June and March 2020, respectively.
Trump, however, dismissed the tariff-induced selloff and said, &#8220;The market is going to boom, the stock is going to boom, the country is going to boom.&#8221;
The 10-year Treasury bond yielded 3.94% and the two-year bond was at 3.61%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> shows markets pricing in a 69.4% likelihood of the Federal Reserve maintaining current interest rates through its May meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.00%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.78%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.54%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.42%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, declined in premarket on Friday. The SPY was down 0.71% to $532.87, while the QQQ declined 0.62% to $447.85, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Technology sectors bore the brunt of Thursday&#8217;s U.S. stock market downturn. Specifically, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares plummeted approximately 9.3%, marking their steepest single-day decline since March 2020. Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) also saw a significant drop, tumbling 7.8%, while Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares fell by 8.98%. Across the broader market, consumer discretionary, energy, and information technology stocks registered the most substantial losses within the S&amp;P 500.
In contrast, consumer staples stocks stood out, bucking the prevailing negative trend and closing the session higher. This sector&#8217;s resilience was highlighted by Lamb Weston Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>), whose shares surged 10% after the company released third-quarter financial results that exceeded expectations and provided FY25 sales guidance above analyst estimates.
Economic data released Thursday presented a mixed picture. U.S. initial jobless claims decreased by 6,000 to 219,000 for the week ending March 29, falling below the anticipated 225,000. Additionally, the U.S. trade deficit narrowed to $122.7 billion in February, improving from $130.7 billion in January and slightly better than the forecasted $123.5 billion. However, the ISM services PMI declined to 50.8 in March, down from 53.5 in February and below market expectations of 53.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-5.97%</td>
<td>16,550.60</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-4.84%</td>
<td>5,396.52</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-3.98%</td>
<td>40,545.93</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-6.59%</td>
<td>1,910.55</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
CNBC&#8217;s Jim Cramer compared Trump&#8217;s tariffs to historical tariff regimes in the U.S., in an X post. he said, &#8220;It is not pro-tariff v. anti-tariff. It&#8217;s about accomplishing what&#8217;s good for our country while not having a Smoot-Hawley situation.&#8221;
The Smoot-Hawley Tariff Act, enacted in 1930, was a US law that significantly increased tariffs on imported goods, intended to protect American businesses and farmers, but ultimately worsened the Great Depression by triggering a global trade war.
However, he added that tariff-induced selloff on Thursday was &#8220;100% Smoot Hawley disguised as thoughtful policy. The market was RIGHT to go down.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It is not pro-tariff v. anti-tariff. It&#39;s about accomplishing what&#39;s good for our country while not having a Smoot Hawley situation. Yesterday was 100% Smoot Hawley disguised as thoughtful policy. The market was RIGHT to go down
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1908066366805991875?ref_src=twsrc%5Etfw">April 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
AQR Capital Management&#8217;s Chief Investment Officer, Cliff Asness, took to X on Thursday to voice his criticism of tariff proponents, specifically disputing the assertion that tariffs result in deflation instead of inflation.
His remarks were a direct response to Anthony Pompliano, the Founder &amp; CEO of Professional Capital Management and a well-known Bitcoin advocate, who had previously claimed, &#8220;Tariffs don't create inflation. The exact opposite happens."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Idiots say this and bray like they've scored a great point. What they mean is giant arbitrary tariffs are so bad they eventually cause recessions which then cause deflation. They then present this as a feature. And if they don't mean that they are even more wrong in some… <a href="https://t.co/ZihK0rbRU0">https://t.co/ZihK0rbRU0</a>
&mdash; Clifford Asness (@CliffordAsness) <a href="https://twitter.com/CliffordAsness/status/1907915579324760564?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Creative Planning&#8217;s chief market strategist, Charlie Bilello, noted that the VIX index reached its highest closing level since Aug. 5, 2024.
He suggested this increase in fear, coupled with lower stock prices, presents enhanced opportunities for investors with a long-term perspective. Bilello also pointed to historical trends, indicating that the S&amp;P 500 has historically delivered &#8220;higher than average&#8221; returns following significant surges in volatility.
He shared data showing that after a comparable spike on Aug. 5, 2024, the S&amp;P 500 returned 6% in one month, 11% in three months, and 18% over six months. On average, Bilello highlighted, the S&amp;P 500 has gained 12% six months after such volatility spikes and 21% after a year.
In an X post, Bilello summarized, &#8220;More Fear = More Opportunity.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The <a href="https://twitter.com/search?q=%24VIX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$VIX</a> spiked nearly 40% higher today and closed above 30 for the first time since last August. What has happened in the past following the biggest volatility spikes? Higher than average forward S&amp;P 500 returns. More Fear = More Opportunity<a href="https://t.co/wMMGtwYloS">https://t.co/wMMGtwYloS</a> <a href="https://t.co/vVEN5vUBD1">pic.twitter.com/vVEN5vUBD1</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1907910013743722855?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Friday:
<ul>
<li>March&#8217;s U.S. employment report, unemployment rate, and hourly wages data will be out by 8:30 a.m. ET.</li>
</ul>
<ul>
<li>Fed Chairman Jerome Powell will speak at 11:25 a.m. ET.</li>
</ul>
<ul>
<li>Fed Governor Michael Barr will speak at 12:00 p.m. and Fed Governor Christopher Waller will speak at 12:45 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>American Shared Hospital Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMS#NYSE">AMS</a>) was up 0.34% in premarket on Friday ahead of its earnings before the opening bell. Analysts expect a quarterly earnings of 1 cent per share on revenue of $7.70 million.</li>
</ul>
<ul>
<li>Neuroone Medical Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) slumped 36.05% after the company disclosed a common stock public offering.</li>
</ul>
<ul>
<li>Simulations Plus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) was up 2.50% after posting stronger-than-expected results for its second quarter and issuing an upbeat FY25 earnings forecast.</li>
</ul>
<ul>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) surged 32.41% after announcing a new agreement with pharmaceutical giant Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), granting the company a worldwide exclusive license to leverage the company&#8217;s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.</li>
</ul>
<ul>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) jumped 3.98% after its CEO, Ryan Cohen, acquired 500,000 shares of the company.</li>
</ul>
<ul>
<li>BioNexus Gene Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) dropped 26.96% after the company said that it will enact a 1-for-10 reverse stock split effective Monday to meet Nasdaq&#8217;s bid price requirements.</li>
</ul>
<ul>
<li>Mullen Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) zoomed 83.64% after it stated that its U.S.-assembled Mullen and Bollinger commercial EV inventory is tariff-exempt.</li>
</ul>
<ul>
<li>CXApp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) gained 40.06% after the company reported business performance results for 2024 and announced a net revenue retention rate of 101%.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 3.57% to hover around $64.56 per barrel.
Gold Spot US Dollar declined 0.97% to hover around $3,083.92 per ounce. Its fresh record high stood at $3,168.04 per ounce. The U.S. Dollar Index spot was higher by 0.48% at the 102.564 level.
Asian markets closed on a lower note on Friday. India's S&amp;P BSE Sensex, Japan's Nikkei 225, Australia's ASX 200, China&#8217;s CSI 300, Hong Kong's Hang Seng, and South Korea's Kospi index fell. European markets were also lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44642317/sp-500-plummets-108-nasdaq-100-corrects-141-since-trumps-inauguration-heres-how-it-compares-to-obama-and-biden-eras">S&amp;P 500 Plummets 10.8%, Nasdaq 100 Corrects 14.1% Since Trump&#8217;s Inauguration: Here&#8217;s How It Compares To Obama And Biden Eras</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Equities

Market Summary

Futures

Commodities

Economics

Federal Reserve

Analyst Ratings

ETFs

AMZN

BGLC

NMTC

Stocks Set To Continue Crashing After Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert

Shares of Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) rose sharply in today's pre-market trading after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), granting the company a worldwide exclusive license to leverage the company&#8217;s novel proprietary neurotropic adeno-associated virus (AAV) <a href="https://www.benzinga.com/quote/sgmo">capsid, STAC-BBB.</a>
Sangamo Therapeutics shares jumped 39.5% to $0.8684 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) gained 115.3% to $0.9990 in pre-market trading after falling around 19% on Thursday.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) rose 82% to $0.1447 in pre-market trading after dipping over 22% on Thursday.</li>
<li>Wellchange Holdings Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) rose 69.4% to $0.3303 in pre-market trading after jumping 23% on Thursday.</li>
<li>Olema Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) rose 49.3% to $5.00 in pre-market trading.</li>
<li>Entero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) gained 40.1% to $0.6123 in pre-market after gaining 6% on Thursday.</li>
<li>CXApp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) surged 37.6% to $1.11 in pre-market trading after the company reported business performance results for 2024 and announced a net revenue retention rate of 101%.</li>
<li>Soho House &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) gained 20% to $7.09 in pre-market trading following a 5% decline on Thursday.</li>
<li>Lionsgate Studios Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) gained 11.1% to $7.90 in pre-market trading after falling 6% on Thursday.</li>
<li>Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) rose 4.5% to $9.61 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Lesaka Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSAK#NASDAQ">LSAK</a>) fell 57.8% to $2.00 in pre-market trading.</li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) shares fell 48.7% to $6.31 in pre-market trading following a 5% decline on Thursday.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) declined 38.3% to $2.01 in pre-market trading.</li>
<li>Greenfire Resources Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFR#NYSE">GFR</a>) fell 22.6% to $4.21 in pre-market trading after dipping 9% on Thursday.</li>
<li>MeridianLink, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) dipped 20.5% to $13.99 in pre-market trading after falling 4% on Thursday.</li>
<li>Insteel Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>) shares tumbled 18.3% to $20.11 in pre-market trading. Insteel Industries will announce its second quarter 2025 earnings on Thursday, April 17.</li>
<li>Global Industrial Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIC#NYSE">GIC</a>) fell 17.3% to $18.00 in today's pre-market trading after dipping 5% in Thursday.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) fell 16.7% to $6.16 in pre-market trading after dipping 7% on Thursday.</li>
<li>Heritage Insurance Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NYSE">HRTG</a>) shares dipped 16.1% to $13.11 in pre-market trading.</li>
<li>Emerald Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) shares fell 15.7% to $3.21 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44641655/guess-simulations-plus-and-3-stocks-to-watch-heading-into-friday">Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects American Shared Hospital Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMS#NYSE">AMS</a>) to report quarterly earnings at 1 cent per share on revenue of $7.70 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. American Shared Hospital Services shares rose 0.3% to $2.97 in after-hours trading.</li>
<li>Guess? Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) reported upbeat results for its fourth quarter and named Alberto Toni as CFO. The company said it sees FY26 revenue to increase 3.9% &#8211; 6.2% in US Dollars and adjusted EPS of $1.32 &#8211; $1.76. Guess shares fell 2.4% to $9.80 in the after-hours trading session.</li>
<li>NeuroOne Medical Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) disclosed a common stock public offering. NeuroOne Medical shares dipped 36.1% to $0.5499 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Simulations Plus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) posted stronger-than-expected results for its second quarter and issued upbeat FY25 earnings forecast. Simulations Plus shares gained 2.5% to $24.41 in the after-hours trading session.</li>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) announced a new agreement with pharmaceutical giant Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), granting the company a worldwide exclusive license to leverage the company's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB. Sangamo Therapeutics shares jumped 47.7% to $0.9193 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44626468/top-3-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday

Sangamo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares are surging in Thursday&#8217;s after-hours session after the company announced a new agreement with <a href="https://www.benzinga.com/pressreleases/25/04/b44635260/sangamo-therapeutics-announces-capsid-license-agreement-with-lilly-to-deliver-genomic-medicines-fo">pharmaceutical giant Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</a>.
What Happened: Sangamo Therapeutics entered into a license agreement with Eli Lilly, granting the company a worldwide exclusive license to leverage the company&#8217;s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.
Sangamo noted that STAC-BBB has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates.
The genomic medicine company said the license allows Eli Lilly to utilize the STAC-BBB capsid for one initial target. Eli Lilly has the right to add up to four additional targets, but will be required to pay additional license fees.
Sangamo will receive an upfront payment of $18 million and is eligible to earn up to $1.4 billion in additional license fees and milestone payments.
&#8220;We believe STAC-BBB, our industry-leading intravenously delivered AAV capsid, has the potential to play an important role in the treatment landscape by addressing longstanding challenges associated with delivering therapies to the central nervous system,&#8221; said Sandy Macrae, CEO of Sangamo.
&#8220;We are pleased to be sharing STAC-BBB with Lilly to advance potential treatments for neurological diseases with significant unmet medical needs. This marks the third agreement with a pharmaceutical company since we announced the discovery of STAC-BBB in March 2024 and demonstrates the continued industry interest in our capsid delivery technology.&#8221;
Sangamo will be responsible for completing a technology transfer related to the STAC-BBB capsid. Lilly will be responsible for all research, preclinical and clinical development, regulatory interactions, manufacturing and global commercialization of any resulting gene therapy products.
SGMO Price Action: <a href="http://benzinga.com/quote/sgmo">Sangamo shares</a> were up 26.13% after hours, trading at 78 cents at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Sangamo Therapeutics.

Biotech

Health Care

After-Hours Center

Sangamo Therapeutics Stock Surges After The Bell: What's Going On?

Sangamo Therapeutics Enters Capsid License Agreement With Lilly; To Receive $18M Upfront License Fee And Is Eligible To Earn Up To $1.4B In Additional Licensed Target Fees And Milestone Payments

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound <a href="https://www.benzinga.com/quote/HIMS">through its Telehealth platform</a>.
What To Know: In a blog post released Tuesday afternoon, Hims &amp; Hers Health announced that it&#8217;s expanding access to personalized weight loss care.
&#8220;We're committed to bringing our customers more treatment options that best suit their needs, and we've now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,&#8221; the company said.
Tirzepatide is the active ingredient in Eli Lilly&#8217;s diabetes and weight-loss drugs. Hims &amp; Hers said it will offer both Lilly&#8217;s Zepbound and Mounjaro on its platform, as well as generic versions of Novo Nordisk&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) liraglutide, per Reuters.
Check This Out: <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44588076/us-manufacturing-slips-into-contraction-as-tariff-driven-costs-hit-near-3-year-high">US Manufacturing Slips Into Contraction As Tariff-Driven Costs Hit Near 3-Year High</a>
&#8220;Medication helps the body manage the biological factors that affect weight. Nutrition fuels the body. Physical activity builds strength and resilience. And behavioral support helps form lasting habits that create real, lifelong change,&#8221; the company said.
&#8220;Through our platform, we're weaving all of these tools together to provide access to a truly comprehensive care experience to deliver the best solution for every individual.&#8221;
Hims &amp; Hers joins competitors Teladoc and LifeMD in offering Lilly&#8217;s Zepbound on its platform. The move comes after a U.S. judge shut down an injunction earlier this month that would have allowed companies to continue making compounded drugs. Regulators allow compounded versions of drugs to enter the market to meet demand when there is a shortage.
HIMS Price Action: <a href="http://benzinga.com/quote/hims">Hims &amp; Hers Health shares</a> were up 6.01% at $31.27 at the time of publication Tuesday afternoon, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$50.00</td>
<td>$160.0K</td>
<td>4</td>
<td>2.0K</td>
</tr>
<tr>
<td>VRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$70.00</td>
<td>$55.4K</td>
<td>372</td>
<td>500</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$28.3K</td>
<td>6.7K</td>
<td>302</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$310.00</td>
<td>$25.5K</td>
<td>8.7K</td>
<td>173</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$40.00</td>
<td>$25.8K</td>
<td>0</td>
<td>150</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$37.00</td>
<td>$47.8K</td>
<td>839</td>
<td>114</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$690.00</td>
<td>$37.0K</td>
<td>212</td>
<td>33</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$77.50</td>
<td>$36.0K</td>
<td>1.4K</td>
<td>26</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$470.00</td>
<td>$32.8K</td>
<td>2</td>
<td>11</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$680.00</td>
<td>$124.6K</td>
<td>10</td>
<td>11</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding IRON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on April 17, 2025. Parties traded 2000 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $160.0K, with a price of $80.0 per contract. There were 4 open contracts at this strike prior to today, and today 2000 contract(s) were bought and sold. 
• For VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we notice a call option sweep that happens to be bearish, expiring in 45 day(s) on May 16, 2025. This event was a transfer of 241 contract(s) at a $70.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $55.4K, with a price of $230.0 per contract. There were 372 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 290 day(s) on January 16, 2026. This event was a transfer of 59 contract(s) at a $25.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $480.0 per contract. There were 6708 open contracts at this strike prior to today, and today 302 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on April 17, 2025. Parties traded 37 contract(s) at a $310.00 strike. The total cost received by the writing party (or parties) was $25.5K, with a price of $690.0 per contract. There were 8768 open contracts at this strike prior to today, and today 173 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option sweep that happens to be bullish, expiring in 16 day(s) on April 17, 2025. This event was a transfer of 150 contract(s) at a $40.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $170.0 per contract. There were 0 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, expiring in 108 day(s) on July 18, 2025. This event was a transfer of 90 contract(s) at a $37.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $47.8K, with a price of $532.0 per contract. There were 839 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bullish sentiment. It expires in 45 day(s) on May 16, 2025. Parties traded 30 contract(s) at a $690.00 strike. The total cost received by the writing party (or parties) was $37.0K, with a price of $1236.0 per contract. There were 212 open contracts at this strike prior to today, and today 33 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a put option trade with bearish sentiment. It expires in 290 day(s) on January 16, 2026. Parties traded 24 contract(s) at a $77.50 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $1500.0 per contract. There were 1454 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• For TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we notice a call option trade that happens to be bearish, expiring in 45 day(s) on May 16, 2025. This event was a transfer of 10 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $32.8K, with a price of $3280.0 per contract. There were 2 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
• Regarding MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we observe a call option trade with bearish sentiment. It expires in 654 day(s) on January 15, 2027. Parties traded 11 contract(s) at a $680.00 strike. The total cost received by the writing party (or parties) was $124.6K, with a price of $11330.0 per contract. There were 10 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKRO

IRON

MRNA

VRNA

10 Health Care Stocks With Whale Alerts In Today's Session

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) revealed 156 unusual trades.
Delving into the details, we found 55% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 108 were puts, with a value of $6,109,986, and 48 were calls, valued at $4,158,923.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $390.0 to $1180.0 for Eli Lilly during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 212.74 with a total volume of 6,503.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $390.0 to $1180.0 over the last 30 days.
<h3>Eli Lilly Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743524137_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/11/25</td>
<td>$22.45</td>
<td>$22.4</td>
<td>$22.4</td>
<td>$815.00</td>
<td>$223.7K</td>
<td align="right">54</td>
<td align="right">316</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$87.3</td>
<td>$84.7</td>
<td>$85.94</td>
<td>$770.00</td>
<td>$222.7K</td>
<td align="right">10</td>
<td align="right">67</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$22.55</td>
<td>$22.35</td>
<td>$22.55</td>
<td>$815.00</td>
<td>$169.5K</td>
<td align="right">54</td>
<td align="right">115</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$88.65</td>
<td>$82.95</td>
<td>$85.95</td>
<td>$770.00</td>
<td>$163.3K</td>
<td align="right">10</td>
<td align="right">34</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$86.95</td>
<td>$84.85</td>
<td>$85.39</td>
<td>$770.00</td>
<td>$102.4K</td>
<td align="right">10</td>
<td align="right">133</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>With a volume of 959,932, the price of LLY is down -1.09% at $816.88. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 30 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $1100.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Eli Lilly, targeting a price of $1100. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Check Out What Whales Are Doing With LLY

Michael Kratsios, a former deputy to venture capitalist Peter Thiel and one of Silicon Valley's most influential tech policy figures, has taken charge of the U.S. government's AI strategy amid escalating competition with China's tech giants.
What Happened: Kratsios was confirmed by the Senate to lead the Office of Science and Technology Policy (OSTP) last week.
His appointment comes as the Donald Trump administration intensifies its scrutiny of China's growing AI capabilities, especially following the emergence of DeepSeek—a Chinese AI startup that developed a powerful model at <a href="https://in.benzinga.com/25/03/44392370/nvidia-destroys-420-billion-of-investor-wealth-since-deepseek-launch-valuation-hits-a-29-month-low-as-gtc-fails-to-ignite-stock">significantly lower costs</a> than its U.S. counterparts.
Having served in the first Trump administration and later overseeing research initiatives at the Department of Defense, Kratsios is no stranger to navigating the intersection of national security and technological innovation, <a href="https://www.wsj.com/politics/policy/trump-ai-michael-kratsios-peter-thiel-protege-1457e276?mod=hp_listb_pos3">reported</a> the Wall Street Journal.
See Also: <a href="https://www.benzinga.com/tech/25/03/44577187/sam-altman-led-openai-releases-open-weight-ai-model-with-reasoning-capabilities-as-deepseek-and-meta-taste-success">Sam Altman-Led OpenAI Releases Open-Weight AI Model With Reasoning Capabilities As DeepSeek And Meta Taste Success</a>
Before returning to government, Kratsios worked at Scale AI, a startup specializing in AI training data.
Now, one of Kratsios's immediate tasks is reviewing thousands of industry submissions for the administration's AI policy framework, the report noted.
He also brings a global perspective to the role, having previously advised U.S. allies against adopting Chinese telecom infrastructure, particularly Huawei Technologies's 5G equipment.
Kratsios will be working alongside other high-profile figures in the administration, including David Sacks, Trump's <a href="https://www.benzinga.com/24/12/42356067/venture-capitalist-david-sacks-appointed-as-white-house-ai-crypto-czar-by-trump">AI and crypto policy leader</a>, and Sriram Krishnan, a senior AI advisor.
Why It's Important: Previously, Chinese President Xi Jinping expressed concerns that the tensions with the U.S. <a href="https://in.benzinga.com/25/03/44161587/is-china-apprehensive-of-losing-the-trade-war-to-the-us-china-could-get-isolated-like-moscow-fears-xi-jinping">could lead to China&#8217;s isolation</a>, similar to the Soviet Union&#8217;s during the Cold War.
Moreover, in response to the U.S. economic offensive, China has reportedly been considering <a href="https://in.benzinga.com/news/global/25/03/44448798/china-ponders-export-limitations-to-quell-trumps-trade-onslaught">restricting certain exports</a> to the U.S.
In March 2025, the U.S. added over <a href="https://in.benzinga.com/news/global/25/03/44494896/us-adds-50-chinese-entities-to-export-restriction-list-curtailing-access-to-nvidia-amd-chips">50 Chinese entities to an export restriction</a> list, limiting their access to advanced technologies like those from Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>).
Meanwhile, China is <a href="https://in.benzinga.com/markets/25/03/44451449/china-courts-apple-pfizer-eli-lilly-amid-us-pressure-vice-premier-says-beijing-will-continue-to-improve-the-business-environment">actively courting multinational companies</a>, including Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), to improve its business environment and attract foreign investment.
Photo by asiandelight on Shutterstock
Read Next:
<ul>
<li><a href="https://benzinga.com/25/03/44554189/openai-and-microsoft-back-mcp-standard-in-major-shift-toward-interoperable-ai-agents-that-can-think-click-and-navigate-the-web-but-google-ceo-sundar-pichai-appears-to-be-mulling-over-it-in-shakespearean-fashion-to-mcp-or-not-to-mcp" target="_blank" rel="noreferrer noopener">OpenAI And Microsoft Back MCP Standard For Web-Surfing AI Agents; Google's Sundar Pichai Asks A Shakespearean Question</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Who Is Peter Thiel's Protégé, Michael Kratsios, Now Leading Trump's AI Strategy Amid Rising Tech Tensions With China

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), on Sunday, announced <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44552764/lillys-lepodisiran-reduced-levels-of-genetically-inherited-heart-disease-risk-factor-lipoprotein-a" rel="noreferrer noopener">positive Phase 2 results</a> for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.
In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the primary endpoint.
Participants who received the 16 mg and 96 mg lepodisiran doses experienced a 40.8% reduction and a 75.2% reduction in Lp(a) levels over the same time period, respectively.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44544761/european-drug-regulator-gives-thumbs-down-to-eli-lillys-alzheimers-drug-analyst-says-it-is-incremental-win-for-biogen" rel="noreferrer noopener">European Drug Regulator Gives Thumbs Down To Eli Lilly&#8217;s Alzheimer&#8217;s Drug, Analyst Says It Is Incremental Win For Biogen</a>
Lepodisiran also met additional secondary endpoints, showing reductions in Lp(a) levels following one or two administrations of each of the three tested doses across all timepoints assessed throughout the nearly 18-month-long study.
Results from additional secondary endpoints showed:
<ul>
<li>Participants who received 400 mg of lepodisiran at both baseline and day 180 experienced a 94.8% reduction in average Lp(a) levels over the day 30 to 360 period, which remained 91.0% below baseline at day 360 (~1 year) and 74.2% below baseline at day 540 (~1.5 years).</li>
<li>Lepodisiran also reduced apolipoprotein B (apoB) levels, a separate cholesterol biomarker.</li>
<li>The highest dose (400 mg) of lepodisiran showed 14.1% and 13.7% ApoB reductions from baseline at day 60 and 180, respectively. A second 400 mg lepodisiran dose at day 180 sustained these apoB reductions through day 540.</li>
</ul>
Treatment-emergent adverse events (TEAEs) related to the study drug occurred in 1% (1/69) of the placebo group, 3% (1/36) of the 16 mg group, 12% (9/74) of the 96 mg group, and 14% (20/141) of the pooled 400 mg group. There were no serious adverse events related to lepodisiran treatment.
A single death occurred in the 16 mg dose group due to complications of chronic coronary disease.
One participant in the placebo group was withdrawn from the study drug due to a TEAE; however, no participants receiving lepodisiran experienced a TEAE leading to withdrawal from treatment or the study.
The ACCLAIM-Lp(a) Phase 3 clinical development program, investigating the effect of lepodisiran on the reduction of cardiovascular events in adults with elevated Lp(a), is currently enrolling.
Price Action: LLY stock is down 1.42% at $810.86 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44544107/rokus-next-chapter-analyst-sees-big-gains-from-streaming-and-ad-expansion" target="_blank" rel="noreferrer noopener">Roku&#8217;s Next Chapter: Analyst Sees Big Gains From Streaming And Ad Expansion</a></li>
</ul>
Photo via Shutterstock

Large Cap

General

Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%

Palatin Technologies Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>) on Monday reported topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon-like peptide-1/gastric inhibitory polypeptide <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">(GLP-1/GIP) tirzepatide</a>.
Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide is available as Mounjaro and Zepbound for diabetes and weight loss.
Topline data results from the study were highly statistically significant for the study&#8217;s primary endpoint, which was percent weight loss in patients for the co-administration of MC4R agonist bremelanotide plus&nbsp;GLP-1/GLP tirzepatide compared to placebo, over the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44558732/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1gip-tirzepatide-meets-prima" rel="noreferrer noopener">8-week treatment period</a>.
<ul>
<li>The co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44536083/palatin-technologies-touts-positive-results-from-mid-stage-study-for-experimental-drug-for-ulcerative-colitis-halts-patients-enrollment-citing-strategic-focus" rel="noreferrer noopener">Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus</a>
The primary analysis for additive effect demonstrated that:
<ul>
<li>40% of patients in the co-administered group achieved a 5% reduction in their body weight, compared to 27% for the tirzepatide alone group.</li>
<li>27% of patients in the co-administered group achieved a 6% reduction in their body weight, compared to 13% for the tirzepatide alone group.</li>
<li>19% of patients in the co-administered group achieved a 7% reduction in their body weight, compared to 0% for the tirzepatide alone group.</li>
</ul>
Over 50% of the lost weight was regained within two weeks after treatment cessation in both the co-administration and the tirzepatide-only groups, a common occurrence following the discontinuation of&nbsp;GLP-1/GIP therapy.
The data indicated that weight regain was effectively halted in the MC4R agonist bremelanotide group.
Additionally, co-administration of the MC4R agonist with the&nbsp;GLP-1/GIP therapy showed no increase in safety or tolerability concerns among patients.
Further data analysis is ongoing, including exploratory endpoints such as body composition and body mass index.
Palatin is advancing the development of its next-generation MC4R long-acting peptide and oral small molecule compounds as stand-alone treatments, as well as in combination with&nbsp;GLP-1/GIP (incretin therapy), and as monotherapy for multiple genetic obesity disorders.
Investigational New Drug applications are expected to be submitted in the fourth quarter of calendar 2025, with clinical data expected in the first half of 2026.
Price Action: PTN stock is down 14.6% at $0.5656 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/emerging-markets/25/03/44563420/despite-us-expansion-taiwan-semiconductor-reaffirms-commitment-to-home-base-with-new-initiatives-reuters" target="_blank" rel="noreferrer noopener">Despite US Expansion, Taiwan Semiconductor Reaffirms Commitment To Home Base With New Initiatives: Reuters</a></li>
</ul>
Photo via Shutterstock.

Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight

<ul>
<li>In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor, with some patients sustaining reductions for nearly 1.5 years</li>
<li>These data were presented at the American College of Cardiology 2025 Scientific Sessions and simultaneously published in the New England Journal of Medicine (NEJM)</li>
</ul>

Reported Earlier, Lilly's Investigational siRNA Therapy Lepodisiran Shows Near-Complete Lp(a) Suppression For Up To 1.5 Years In Phase 2 Study

Benzinga examined the prospects for<a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener"> many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
U.S. stock markets declined this week amid escalating trade tensions and inflation concerns. The S&amp;P 500 fell 2%, the Dow Jones Industrial Average dropped 1.7%, and the Nasdaq Composite decreased by 2.7%, marking one of the worst weeks in recent years.
President Donald Trump's announcement of a 25% tariff on imported automobiles and parts contributed to market volatility. Automotive stocks were notably impacted; General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) tumbled over 7%, and Ford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) slid 3.9%. Conversely, electric vehicle manufacturers like Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) edged up 0.4%, as their U.S.-based production is less affected by the tariffs.
Beyond the auto sector, economic indicators added to investor unease. The Federal Reserve's preferred inflation gauge, the core Personal Consumption Expenditures (PCE) price index, rose 0.4% in February, bringing the annual rate to 2.8%, above the Fed's 2% target. Additionally, consumer spending data fell short of expectations, exacerbating fears of economic slowdown amid President Trump's tariff policies.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44512999/chevron-hits-52-week-high-warren-buffetts-5th-largest-holding-is-on-fire-but-should-you-buy">"Chevron Hits 52-Week High: Warren Buffett's 5th Largest Holding Is On Fire — But Should You Buy?"</a>, by Surbhi Jain, reports that Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) hit a 52-week high as rising oil prices and Warren Buffett's ongoing support strengthened investor confidence.
<a href="https://www.benzinga.com/media/25/03/44515782/microsoft-halts-expansion-plans-yet-analysts-still-rank-it-among-top-investment-picks">"Microsoft Halts Expansion Plans, Yet Analysts Still Rank It Among Top Investment Picks"</a>, by Anusuya Lahiri, explains why analysts remain bullish on Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) despite the tech giant pausing major data center expansions amid concerns of AI overcapacity.
<a href="https://www.benzinga.com/analyst-ratings/upgrades/25/03/44477982/carvana-analyst-says-its-time-to-buy-the-potential-amazon-of-auto-retail">"Carvana Analyst Says It's Time To Buy The Potential ‘Amazon Of Auto Retail'"</a>, by Adam Eckert, reports that Morgan Stanley analyst Adam Jonas upgraded Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) from Equal-Weight to Overweight, raising the price target from $260 to $280, citing the company's potential to dominate auto retail akin to Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/news/earnings/25/03/44504468/concentrix-shares-pop-on-strong-q1-results-raised-revenue-guidance">Concentrix Shares Pop On Strong Q1 Results, Raised Revenue Guidance</a>
<a href="https://www.benzinga.com/trading-ideas/technicals/25/03/44517249/stock-of-the-day-will-the-move-higher-in-sysco-continue">Stock Of The Day – Will The Move Higher In Sysco Continue?</a>
<a href="https://www.benzinga.com/trading-ideas/technicals/25/03/44460563/tesla-jumps-10-on-china-fsd-optimism-tariff-easing-hopes">Tesla Jumps 10% On China FSD Optimism, Tariff Easing Hopes</a>

The Bears
<a href="https://www.benzinga.com/general/biotech/25/03/44500068/novo-nordisk-stock-sinks-to-52-week-lows-weight-loss-boom-losing-steam">"Novo Nordisk Stock Sinks To 52-Week Lows: Weight Loss Boom Losing Steam?"</a>, by Surbhi Jain, reports that Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares have plunged 44% year-over-year, hitting a 52-week low amid investor concerns over competition from Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and the company's recent $2 billion acquisition of rights to a Chinese obesity drug.
<a href="https://www.benzinga.com/trading-ideas/technicals/25/03/44513787/nike-stock-hits-52-week-lows-is-the-sneaker-king-losing-its-step">"Nike Stock Hits 52-Week Lows: Is The Sneaker King Losing Its Step?"</a>, by Surbhi Jain, shows Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) tumbling to a 52-week low as slowing sales in China and rising competition challenge the global sneaker giant's dominance.
<a href="https://www.benzinga.com/25/03/44475805/homebuilders-kb-home-lennar-cut-prices-as-homebuyer-demand-has-slowed-materially">"Homebuilders KB Home, Lennar Cut Prices As Homebuyer Demand Has Slowed Materially"</a>, by Erica Kollmann, reports that KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) and Lennar Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) are reducing home prices and offering incentives as elevated mortgage rates have significantly dampened buyer demand.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/25/03/44517020/ev-maker-mullen-automotive-to-further-cut-costs-and-slash-workforce">EV Maker Mullen Automotive To Further Cut Costs And Slash Workforce: Details</a>
<a href="https://www.benzinga.com/25/03/44465410/snow-white-disappoints-at-box-office-will-remake-hurt-disneys-marvel-magic-in-2025">‘Snow White' Disappoints At Box Office: Will Remake Hurt Disney's Marvel Magic In 2025?</a>
<a href="https://www.benzinga.com/news/offerings/25/03/44511664/why-is-teslas-chinese-rival-nio-stock-diving-today">Why Is Tesla's Chinese Rival NIO Stock Diving Today? (UPDATED)</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

CVNA

MSFT

TSLA

Benzinga Bulls And Bears: Chevron, Microsoft, Nike — And Tariffs Have Automotive Sector Reeling

Last week, Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) co-founder and philanthropist Bill Gates lamented the growing divide between the U.S. and China, saying it's blocking access to critical climate and technology innovations.
What Happened: In a wide-ranging interview during an Express Adda event, Gates praised China's leadership in renewable energy, artificial intelligence, and battery technology, while expressing concern that geopolitical tensions are hindering global collaboration on major challenges like climate change.
"China has been absolutely a pioneer," Gates said, noting its dominance in solar panel manufacturing, battery innovation, and AI research. "It's a real shame for the world that the U.S.-China tension means that the willingness to access those goods is quite limited."
See Also:&nbsp;<a href="https://www.benzinga.com/tech/25/03/44506409/steve-jobs-warned-34-years-ago-about-america-being-hollowed-out-by-foreign-manufacturing-a-concern-trump-now-echoes" target="_blank" rel="noreferrer noopener">Steve Jobs Warned 34 Years Ago About America Being ‘Hollowed Out' By Foreign Manufacturing — A Concern Trump Now Echoes</a>
Gates underscored the scale of China's contributions, calling the country "out in front" on critical green technologies and saying its research institutions have achieved "deep" scientific capabilities.
He pointed to electric vehicles as an area where American tariffs are impeding progress, noting, "There just won't be many Chinese EVs sold in the United States" due to high import barriers.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It's Important: Gates' comments come as the U.S. and China remain locked in strategic and economic competition, particularly around semiconductors, clean energy, and AI.
Earlier this week, the U.S. added over <a href="https://in.benzinga.com/news/global/25/03/44494896/us-adds-50-chinese-entities-to-export-restriction-list-curtailing-access-to-nvidia-amd-chips">50 Chinese entities to an</a> export restriction list, aiming to curb China&#8217;s advancements in AI and semiconductor technology. This move is part of a broader strategy to limit China&#8217;s access to cutting-edge technology from companies like NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>).
Meanwhile, China has been <a href="https://in.benzinga.com/markets/25/03/44451449/china-courts-apple-pfizer-eli-lilly-amid-us-pressure-vice-premier-says-beijing-will-continue-to-improve-the-business-environment">actively courting multinational companies</a>, including Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), to improve its business environment amidst these pressures.
China is reportedly considering <a href="https://in.benzinga.com/news/global/25/03/44448798/china-ponders-export-limitations-to-quell-trumps-trade-onslaught">export restrictions</a> in response to U.S. economic actions.
Additionally, talks are ongoing about a <a href="https://in.benzinga.com/news/global/25/03/44235317/trump-xi-discuss-potential-birthday-summit-amid-rising-trade-tensions-report">possible &#8220;birthday summit&#8221; between</a> Donald Trump and Chinese President Xi Jinping in June.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Bill Gates Exclusive Interview on Future of Tech, AI &amp; Global Impact &#x7C; Bill Gates Latest Interview" width="500" height="281" src="https://www.youtube.com/embed/Iq1yfTbrWyw?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44487688/signal-touts-gold-standard-encryption-as-trump-administration-leak-spotlight-intensifies-our-code-is-regularly-scrutinized" target="_blank" rel="noreferrer noopener">Signal Touts ‘Gold Standard' Encryption As Trump Administration Leak Spotlight Intensifies: ‘Our Code Is Regularly Scrutinized'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Global

Microsoft Co-Founder Bill Gates Praises China As A Pioneer In Solar, Batteries, And AI: Warns Tensions Are Stifling Global Innovation

LLY RISES 8 POINTS AFTER ALERT
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/28202809/Screenshot-2025-03-28-at-4.24.08%E2%80%AFPM-996x1024.png" alt="" class="wp-image-9235" /></figure>
Eli Lilly &amp; Co. (LLY) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:33 AM on March 28th, a significant trading signal occurred for Eli Lilly &amp; Co. (LLY) as it demonstrated a Power Inflow at a price of $821.70. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Lilly&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Lillys stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for LLY, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:The price at the time of the Power Inflow was $821.70. The returns on the High price ($829.78) and Close price ($822.51) after the Power Inflow are respectively 1.0% and 0.1%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk.
Past Performance is not indicative of future results

Technicals

Opinion

Signals

Eli Lilly Stock Up 1% After Key Signal, Despite S&P 500's ~2% Drop

President Trump Says Will Be Announcing Pharma Tariffs Soon

European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued an opinion that does not recommend Eli Lilly and Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) donanemab be granted marketing authorization for the treatment of early symptomatic Alzheimer's disease. Lilly will seek <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">re-examination by CHMP</a>.
Kisunla (donanemab) is <a target="_blank" href="https://investor.lilly.com/news-releases/news-release-details/lillys-statement-about-chmp-opinion-issued-donanemab" rel="noreferrer noopener">used</a> to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding" rel="noreferrer noopener">Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a>
In October 2024, Eli Lilly released results from the TRAILBLAZER-ALZ 6 Phase&nbsp;3b&nbsp;study to investigate different dosing regimens of donanemab and their effect on amyloid-related imaging abnormalities with edema/effusion (ARIA-E) in adults with early&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41608511/eli-lilly-says-new-data-can-potentially-provide-path-to-improved-donanemab-profile-by-lower-risk-" rel="noreferrer noopener">symptomatic Alzheimer's disease</a>.
The data showed a reduction in amyloid-related imaging abnormalities with edema/effusion (ARIA-E) at the 24-week primary endpoint for people receiving a slightly modified titration of donanemab in adults with early symptomatic Alzheimer's disease.
On Thursday, Eli Lilly expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth options for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44513552/lillydirect-platform-expands-to-facilitate-access-to-alzheimers-disease-care" rel="noreferrer noopener">Alzheimer's patients in the U.S.</a>
William Blair views "the CHMP's negative opinion on Kisunla as unsurprising, given the initial negative opinion for Leqembi, but nonetheless view it as an incremental win for Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) and Eisai."
Analyst Myles Minter writes that given that the CHMP changed its stance to support Biogen's Leqembi after a formal review, it's highly likely that Lilly will challenge Friday's decision. Historically, appeals in European marketing application authorization (MAA) filings have led to a reversal about 25% of the time.
William Blair estimates that Leqembi's sales in the EU could reach $1.3 billion by 2031. Analyst Minter sees Leqembi as a growth driver for Biogen, especially if advancements like a potential subcutaneous version get approved. However, sales are growing more slowly than expected.
The analyst reiterates Biogen's Outperform rating but acknowledges that without substantial M&amp;A activity, this is a show-me story about returning to growth with the current portfolio.
Price Action: BIIB stock is down 1% at $138.92, and LLY stock is down 0.26% at $819.55&nbsp;at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44538151/european-commission-declines-to-renew-marketing-authorization-of-translarna-duchenne-muscular-disorder" target="_blank" rel="noreferrer noopener">European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder</a></li>
</ul>
Image via Shutterstock

Analyst Color

BIIB

European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.51% on an annualized basis producing an average annual return of 14.67%. Currently, Eli Lilly has a market capitalization of $738.30 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 20 years ago, it would be worth $16,007.60 today based on a price of $822.00 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743118208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Eli Lilly 20 Years Ago Would Be Worth Today

ONVO

Organovo Says with The Closing Of The Sale Of Its FXR Program To Lilly, It Has Received Upfront Payments And Anticipates Future Milestone Payments

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has been on a tear in the <a href="https://www.benzinga.com/topic/weight-loss-drug">weight loss drug</a> race, but its stock is slimming down for all the wrong reasons.
Shares have plunged 44.14% over the past year, 17.4% year-to-date, and 19.27% in the last month.
The Novo Nordisk stock fell to a fresh 52-week low of $72.15 — a far cry from its peak of $148.15.
<h2 class="wp-block-heading">NVO Stock Chart: A Bearish Picture</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/26121310/Screenshot-2025-03-26-at-9.42.58-PM.png" alt="" class="wp-image-843028" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/26121310/Screenshot-2025-03-26-at-9.42.58-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/26121310/Screenshot-2025-03-26-at-9.42.58-PM-300x232.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The stock is firmly in bearish territory, trading below its eight, 20, and 50-day exponential moving averages. It&#8217;s a sign that selling pressure isn't letting up. 
The eight-day simple moving average (SMA) of $77.11, 20-day SMA of $81.23 and 50-day SMA of $82.94 all flash bearish signals, while the 200-day SMA of $111.72 highlights just how deep this decline has been.
Adding insult to injury, the MACD (moving average convergence/divergence) reading of a negative 3.04 and RSI (relative strength index) of 32.37 suggest further downside risk.
Read Also: <a href="https://www.benzinga.com/insights/news/25/03/44474102/if-you-invested-1000-in-this-stock-5-years-ago-you-would-have-this-much-today">If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today</a>
<h2 class="wp-block-heading">A New Obesity Drug Bet: Too Little, Too Late?</h2>
While Novo Nordisk is busy betting on the future with its latest <a href="https://www.benzinga.com/general/biotech/25/03/44459637/novo-nordisk-to-pay-around-2-billion-for-obesity-drug-from-china-based-biotech">$2 billion deal</a> to acquire rights to a Chinese obesity drug from United Laboratories International, investors remain unimpressed. 
The treatment, UBT251, is designed to challenge Eli Lilly &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) &#8216;Triple G&#8217; obesity drug, retatrutide, which has already shown promising weight loss results, <a href="https://www.cnbc.com/2025/03/25/healthy-returns-novo-nordisk-buys-united-laboratories-obesity-drug.html">reported</a> CNBC.
But with UBT251 still in early-stage trials, Lilly's blockbuster could hit the market first, leaving Novo Nordisk playing catch-up.
<h2 class="wp-block-heading">Trouble Ahead?</h2>
Novo Nordisk's weight loss empire is facing pressure on multiple fronts—technical signals scream bearish, competition is heating up, and Wall Street is questioning whether the company can maintain its dominance. 
As investors digest the latest drug deal, Novo Nordisk stock bulls may need more than a new obesity treatment to revive the stock's momentum. For now, the trend remains sharply downward.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/03/44490348/exclusive-vivani-medical-subdermal-semaglutide-implant-shows-20-weight-loss-in-animal-study-with-potential-for-once-yearly-dosing" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing</a></li>
</ul>
Image: Shutterstock

Novo Nordisk Stock Sinks To 52-Week Lows: Weight Loss Boom Losing Steam?

Press Releases

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Contracts

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Organovo Provides Business Update

Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

LillyDirect platform expands to facilitate access to Alzheimer's disease care

Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels

Kanvas Bio Publishes New Research on its Novel Spectral Imaging Platform, a Transformative Tool for Microbiome Drug Discovery and Development

ABBV

ATNM

AVIR

CARM

COYA

INCY

MEIP

RIBT

SYBX

TSX:PHO

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Eli Lilly

Noticias

Últimas noticias sobre Eli Lilly (NYSE:LLY) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL